ImageneBio (IMA) Corporate presentation summary

Corporate overview and strategy

• Publicly listed on NASDAQ in July 2025 via reverse merger and financing, headquartered in San Diego.

• Strong investor backing with a cash runway projected into Q1 2028 and $145.3 million pro-forma cash as of April 2026.

• Focused on IMG-007, a differentiated anti-OX40 monoclonal antibody for atopic dermatitis (AD) and alopecia areata (AA), with global commercialization rights.

• Pipeline-in-a-product potential with ongoing and planned studies in multiple autoimmune and inflammatory diseases.

Product differentiation and mechanism

• IMG-007 targets the OX40 receptor, inhibiting OX40-OX40L signaling in both blood and tissues for optimal efficacy.

• Engineered Fc region silences ADCC, preserving T cells for improved safety and tolerability.

• Extended half-life (~5 weeks) enables infrequent dosing, potentially every few months.

• Designed to address unmet needs in AD and AA with features that matter to patients.

Clinical development and proof-of-concept

• Phase 1b/2a in moderate-to-severe AD showed rapid and durable improvement: 87% mean EASI reduction at week 20 after three doses.

• 54% of patients achieved EASI-75 and 31% achieved EASI-90 by week 16, with effects maintained through week 24.

• Favorable safety profile: no serious or treatment-related adverse events, no infusion reactions, and no fever or chills.

• Biomarker analysis showed normalization of Th1, Th2, and Th17 serum proteins.